Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
41 hedge funds and large institutions have $48.7M invested in Viracta Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 9 closing their positions.
1,714% more call options, than puts
Call options by funds: $925K | Put options by funds: $51K
14% more capital invested
Capital invested by funds: $42.9M → $48.7M (+$5.81M)
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 45 → 41 (-4)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.25M |
| 2 |
SCM
Sio Capital Management
New York
|
+$1.27M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$617K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$603K |
| 5 |
BlackRock
New York
|
+$337K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.96M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.09M |
| 3 |
First Eagle Investment Management
New York
|
-$1.04M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$398K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$274K |
VIRX Hedge Fund Activity: Q1 2017 in Review
41 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2017, worth a combined $48.7M — up 14% from $42.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of VIRX and 8 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 10 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $2.25M. The largest seller was Cormorant Asset Management, cutting an estimated $1.96M.
- 41 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2017, down from 45 in Q4 2016.
- Funds reported $48.7M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2017, up 14% quarter-over-quarter.
- 8 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2017 and 9 closed out, a net change of -1 holder.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2017 was Opaleye Management, an estimated $2.25M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2017 was Cormorant Asset Management, an estimated $1.96M sold.
Based on aggregated 13F filings for Q1 2017.